Biocon to merge Biocon Biologics in $5.5 billion deal
Biocon will acquire the residual stake held by Mylan (Viatris) for a total consideration of US$ 815 million
Biocon will acquire the residual stake held by Mylan (Viatris) for a total consideration of US$ 815 million
MRI is particularly valuable in pediatric care due to its non-invasive nature
VitiPure serves as essential solubilizers, emulsifiers, and bioavailability enhancers in drug formulations
The one-time CAR T cell infusion now becomes the first and only therapy of its kind cleared for this patient population
Ipca Laboratories receives three observations from USFDA for API facility at Tarapur
The topical fluralaner solution is cleared for the prevention and treatment of new world screwworm infestation
The center will offer training to super-specialist doctors and healthcare professionals in various fields
This campaign is to raise awareness about the crucial role helmet usage plays in saving lives
Terray and BMS aim to accelerate small molecule drug discovery by harnessing EMMI’s integrated experimental and AI capabilities
Subscribe To Our Newsletter & Stay Updated